Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for INSM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 741.01M
March 31, 2026 743.43M
December 31, 2025 746.52M
September 30, 2025 740.94M
June 30, 2025 739.82M
March 31, 2025 1.306B
December 31, 2024 1.305B
September 30, 2024 1.156B
June 30, 2024 1.373B
March 31, 2024 1.366B
December 31, 2023 1.354B
September 30, 2023 1.347B
June 30, 2023 1.339B
March 31, 2023 1.331B
December 31, 2022 1.321B
September 30, 2022 824.32M
June 30, 2022 825.52M
March 31, 2022 826.66M
December 31, 2021 602.74M
September 30, 2021 595.25M
June 30, 2021 587.43M
March 31, 2021 401.18M
December 31, 2020 393.37M
September 30, 2020 389.91M
June 30, 2020 391.26M
Date Value
March 31, 2020 388.60M
December 31, 2019 386.00M
September 30, 2019 362.42M
June 30, 2019 359.66M
March 31, 2019 357.02M
December 31, 2018 316.56M
September 30, 2018 311.86M
June 30, 2018 307.16M
March 31, 2018 302.71M
December 31, 2017 55.57M
September 30, 2017 55.39M
June 30, 2017 55.19M
March 31, 2017 54.99M
December 31, 2016 54.79M
September 30, 2016 34.68M
June 30, 2016 24.82M
March 31, 2016 24.79M
December 31, 2015 25.14M
September 30, 2015 25.26M
June 30, 2015 25.12M
March 31, 2015 24.99M
December 31, 2014 24.86M
September 30, 2014 19.91M
June 30, 2014 19.81M
March 31, 2014 19.80M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 59.55M
Alnylam Pharmaceuticals, Inc. 2.942B
Biogen, Inc. 8.355B
Gilead Sciences, Inc. 26.25B
Agios Pharmaceuticals, Inc. 11.95M